Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data

Retinal DiseasesFurther Publications

Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis

Am J Ophthalmol

Mikhail D, Tao BK, Yu P, Calicchia L, Butt FR, Dhivagaran T, Al-Qattan HM, Feo A, Quarta A, Mishra AV, Seamone ME, Navajas EV, Kertes PJ, Wong DT, Muni RH, Kaplan AJ, Yan P, Popovic MM

doi: 10.1016/j.ajo.2026.05.042

Macular Diseases

Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Ophthalmol Retina

Goncalves L, Hashimoto Y, Barthelmes D, Barry R, Pollreisz A, Wolff B, Toole LO, Ponsioen TL, Morros HB, Creuzot-Garcher C, Gillies M, Gabrielle PH

doi: 10.1016/j.oret.2026.04.007

Macular DiseasesRetinal Diseases

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Ophthalmol Ther

Heck K, Hatz K, Cattaneo M, Pfister I, Magnin S, Ruscitti L, Stasik I, Tillmann A, Shamshiev M, Fang J, Weinberger A, Zweifel SA, Garweg JG, Eandi CM, Grimaldi G, Munk MR, Somfai GM, Ambresin A, Feltgen N

doi: 10.1007/s40123-026-01442-w

Further Publications

Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

JAMA Ophthalmol

Bordbar DD, Mukhtar AO, Loya A, Alsoudi AF, Muayad J, Chauhan MZ, Patel NA, Sallam AB, Weng CY

doi: 10.1001/jamaophthalmol.2026.0460

Macular Diseases

Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema

Am J Ophthalmol

Kundu R, Goturi N, Green M, Poulaki V, Siegel NH, Subramanian ML, Ness S

doi: 10.1016/j.ajo.2026.09.002

Macular DiseasesRetinal Diseases

Longitudinal Changes in Inner Retinal Layers in Treatment-Naïve Neovascular AMD During Intravitreal Anti-VEGF Therapy

Ophthalmol Retina

Kardo H, Garweg RA, Imbach L, Garweg JG

doi: 10.1016/j.oret.2026.08.031

COMMENTED

Macular DiseasesRetinal Diseases

Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Am J Ophthalmol

Murray M, Schifano F, Chiappini S, Corkery JM, Guirguis A

doi: 10.1016/j.ajo.2025.12.015

Retinal Diseases

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

J Clin Med

Rodríguez-Fernández CA, Oliver-Gutierrez D, Arnaiz A, Pablos T, Segura-Duch G, Zapata MÁ

doi: 10.3390/jcm15124508

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Related content

Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis

Real-World Outcomes in Neovascular AMD with Visit Gaps under Anti-VEGF Therapy: Data from the FRB! Registry

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report

Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

Real-World Applicability of Anti-VEGF Trial Criteria for Diabetic Macular Edema

Longitudinal Changes in Inner Retinal Layers in Treatment-Naïve Neovascular AMD During Intravitreal Anti-VEGF Therapy

Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database

Intravitreal Therapy in Adults Aged ≤50 Years: Etiologic Spectrum, Treatment Patterns and Visual Outcomes in a Real-World Cohort

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report